ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 416

Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient-Derived Versions of Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Disease Activity Score 28 (DAS28)

Erin Carruthers1, Noura AL Osaimi2, Charles H Goldsmith3, Paul Adam4 and Diane Lacaille5, 1Arthritis Research Centre of Canada, Richmond, BC, Canada, 2Rheumatology, University of Ottawa, Ottawa, ON, Canada, 3Health Sciences, Simon Fraser University, Burnaby, BC, Canada, 4Mary Pack Arthritis Centre, Vancouver, BC, Canada, 5Medicine, University of British Columbia, Vancouver, BC, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Disease Activity, Outcome measures, patient engagement, patient outcomes and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity

Session Type: Abstract Submissions (ACR)

Background/Purpose

In RA the target for treatment is clinical remission or minimal disease activity. Patient self- monitoring of disease activity may enhance treatment by providing early warnings when targets are not met, indicating the need to re-evaluate treatment. The objective of this study is to compare agreement between patient and rheumatologist (MD) derived disease activity states using Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Disease Activity Score 28 (DAS28).

Methods

Consecutive RA patients presenting for follow-up to seven rheumatologists were invited to participate. Consenting patients completed a questionnaire and performed a self-report joint count before their visit. MD joint count and lab values were obtained from charts. Disease activity was evaluated using patient and MD versions of CDAI, SDAI and DAS28. In patient versions, patient joint counts were used and MD global assessments were replaced with patient global assessments (for CDAI and SDAI). Disease states were categorized into remission, low, moderate or high, according to published cut points. Because change in treatment is recommended with moderate or high disease activity, we also compared instruments using two categories: remission or low vs. moderate or high. Agreement between patient and MD derived disease states were evaluated using Agreement Coefficient 1 (AC1) for two category comparisons and Agreement Coefficient 2 (AC2), weighted with quadratic weights, for four category comparisons. AC values > 0.62 were considered good agreement. Z tests were used to evaluate the statistical significance of the difference between pairs of ACs. All p values were 2 tailed.

Results

We recruited 150 RA patients [mean (SD) RA duration: 11.9 (11.3) y; age: 57.8 (16.3) y; 81% female]. Table 1 shows agreement between patient and MD derived disease activity measures (all p values < 0.001). There was good agreement between patient and MD derived disease activity states from the same measure, except when comparing patient and MD DAS28 across four categories, which had slightly lower agreement. There was no significant difference in the agreement between the patient and MD versions of the three measures when using four categories [CDAI vs. SDAI AC2: p = 0.480; CDAI vs. DAS28 AC2: p = 0.633; SDAI vs. DAS28 AC2: p = 0.915] or two categories [CDAI vs. SDAI AC1: p = 0.580; CDAI vs. DAS28 AC1: p = 0.052; SDAI vs. DAS28 AC1: p = 0.062].

Conclusion

Our results suggest that patients can self-monitor disease activity using patient derived CDAI, SDAI or DAS28 measures. Good agreement was found between the disease activity states derived from patient data and MD data from the corresponding measure, except for DAS28 when using four categories. There was no statistically significant difference in the agreement across measures.

Table 1. Agreement between patient and MD derived indices measured across four and two disease activity categories.

A

Comparison across four categories (remission vs. low vs. moderate vs. high)

PATIENT MEASURES

RHEUMATOLOGIST MEASURES

 

CDAI-MD

SDAI-MD

DAS28-MD

 

AC2 [95% CI]

AC2 [95% CI]

AC2 [95% CI]

CDAI-Pt

0.67 [0.55, 0.79]

0.67 [0.54, 0.79]

0.43 [0.29, 0.58]

SDAI-Pt

0.62 [0.49, 0.75]

0.68 [0.56, 0.81]

0.39 [0.24, 0.55]

DAS28-Pt

0.55 [0.42, 0.69]

0.50 [0.35, 0.64]

0.58 [0.45, 0.71]

B

Comparison across two categories (remission or low vs. moderate or high)

PATIENT MEASURES

RHEUMATOLOGIST MEASURES

 

CDAI-MD

SDAI-MD

DAS28-MD

 

AC1 [95% CI]

AC1 [95% CI]

AC1 [95% CI]

CDAI-Pt

0.80 [0.75, 0.85]

0.80 [0.75, 0.86]

0.43 [0.29, 0.57]

SDAI-Pt

0.77 [0.72, 0.82]

0.79 [0.74, 0.85]

0.38 [0.24, 0.53]

DAS28-Pt

0.71 [0.64, 0.79]

0.67 [0.58, 0.75]

0.79 [0.72, 0.86]

AC1 = agreement coefficient 1; AC2 = quadratic weighted agreement coefficient 2

All AC values have 2 tailed p-values of p < 0.001

Bolded values (AC > 0.62) are considered good agreement


Disclosure:

E. Carruthers,
None;

N. AL Osaimi,
None;

C. H. Goldsmith,
None;

P. Adam,
None;

D. Lacaille,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-patient-reported-outcome-measures-to-classify-disease-activity-states-in-rheumatoid-arthritis-a-comparison-of-patient-derived-versions-of-clinical-disease-activity-index-cdai-simplified-dise/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology